KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maxlinear (MXL) Research & Development (2016 - 2025)

Historic Research & Development for Maxlinear (MXL) over the last 17 years, with Q4 2025 value amounting to $51.7 million.

  • Maxlinear's Research & Development rose 80.54% to $51.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $208.6 million, marking a year-over-year decrease of 736.71%. This contributed to the annual value of $208.6 million for FY2025, which is 736.71% down from last year.
  • Maxlinear's Research & Development amounted to $51.7 million in Q4 2025, which was up 80.54% from $54.3 million recorded in Q3 2025.
  • In the past 5 years, Maxlinear's Research & Development registered a high of $80.4 million during Q2 2022, and its lowest value of $47.2 million during Q2 2025.
  • Over the past 5 years, Maxlinear's median Research & Development value was $65.6 million (recorded in 2022), while the average stood at $63.9 million.
  • As far as peak fluctuations go, Maxlinear's Research & Development surged by 16592.34% in 2021, and later crashed by 2141.3% in 2024.
  • Over the past 5 years, Maxlinear's Research & Development (Quarter) stood at $73.3 million in 2021, then increased by 0.55% to $73.7 million in 2022, then dropped by 11.49% to $65.2 million in 2023, then dropped by 21.41% to $51.3 million in 2024, then rose by 0.81% to $51.7 million in 2025.
  • Its Research & Development stands at $51.7 million for Q4 2025, versus $54.3 million for Q3 2025 and $47.2 million for Q2 2025.